Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Dec 11, 2023 1:22pm
170 Views
Post# 35778173

RE:Global players...

RE:Global players...If Sirona is going to get their product out on the market and not have to wait 3 f-in years, then this might be progress.

The question is can Geraldine's TFC 1326 beat out Retinol. If it does, and a reasonable mass of community experts agree, and dare I say some real customers as well, then getting to market early will make all the difference to them, to us.

I have been asking the company to supply us shareholders with some of their "as tested" cream formulations to see for ourselves. They seem hesitant for obvious reasons but I know a lot of colleague shareholders that would likely invest more money in this company if they only had the product and supporting real world customer validation in their hands. 

If something works and works that well, then one can't continue to keep it locked in the vault.

Seriously Sirona, get on this and get it out to people who influence this space on social media.


<< Previous
Bullboard Posts
Next >>